ArticleOncoTargets and therapy2017

VTD-melphalan is well tolerated and results in very high rates of stringent CR and MRD-negative status in multiple myeloma.

Kalyan Nadiminti et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.